FIELD: medicine, nephrology. SUBSTANCE: the method deals with testing urinary proteins by automatically controlled electrophoresis in a gradient 8-25%-polyacrylamide gel with dodecyl sodium sulfate detergent. Moreover, protein fractions are studied within 10-330 kDa range. At combining protein fractions of 25-27 kDa mol. weight-α1-microglobulin, α1-acid glycoproteide and 58-75 kDa-prealbumin, albumin, postalbumin the standard is diagnosed. At determining protein fractions of 58-75 kDa mol. weight-prealbumin, albumin, postalbumin, 76-160 kDa-transferrin, monomer THP, haptoglobin, dimeric A1, immunoglobulans G and 161-330 kDa- immunoglobulins' fraction the glomerulopathies are diagnosed. At combining protein fractions of 10-24 kDa mol. weight - γ trace protein, β2-microglobulin, ribonuclease, lysozyme, monomeric hemoglobin, retinolbinding protein, 58-75 kDa - prealbumin, albumin, postalbumin, 76-160 kDa-transferrin, monomer THP, haptoglobin, dimeric A1, immunoglobulin G and 161-330 kDaimmunoglobulins' fraction - a combinative defects of glomerules and canaliculi are diagnosed, that is glomerulonephritis with tubulointerstitial component, at determining uroproteins of 10-24 kDa mol. weight - γ trace protein, β2-microglobulin, ribonuclease, lysozyme, monomeric hemoglobin, retinolbinding protein, 25-27 kDa-α1-microglobulin, α1-acid glycoproteide, 58-75 kDa-prealbumin, albumin, postalbumin, 76-160 kDa-transferrin, monomer THP, haptoglobulin, dimeric A1, immunoglobulin G the tubulointerstitial nephritis and tubulopathies are diagnosed. EFFECT: higher accuracy of differentiated diagnostics of renal diseases. 3 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DIAGNOSTICS OF DIABETIC NEPHROPATHY AT PRE-CLINICAL STAGE | 2007 |
|
RU2348038C1 |
METHOD FOR MEASURING HUMAN MEGALINE | 2007 |
|
RU2463608C2 |
CELLULAR SYSTEM FOR TARGETED DELIVERY OF A PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL | 2016 |
|
RU2771323C2 |
FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
RECOMBINANT ROBO2 PROTEINS, COMPOSITIONS, METHODS AND THEIR USE | 2018 |
|
RU2791486C2 |
TREATING KIDNEY DISEASE IN SUBJECTS WITH RENAL AND/OR URINARY TRACT ABNORMALITIES | 2020 |
|
RU2823980C2 |
PHARMACEUTICAL COMPOSITION OF ANTI-CD20 ANTIBODY AND USE THEREOF | 2022 |
|
RU2824627C2 |
COMPOSITIONS CONTAINING CELL VESICLES AND USE THEREOF | 2019 |
|
RU2824136C2 |
IMMUNOLOGICALLY PRIVILEGED BIOACTIVE KIDNEY CELLS FOR TREATMENT OF KIDNEY DISEASE | 2018 |
|
RU2816753C2 |
ANTAGONISTS AND METHOD OF USING SAID ANTAGONISTS | 2005 |
|
RU2401842C2 |
Authors
Dates
2002-03-27—Published
2000-07-03—Filed